Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer’s Disease by Blanco Palmero, Víctor Antonio et al.
biomedicines
Article
Increased YKL-40 but Not C-Reactive Protein Levels in Patients
with Alzheimer’s Disease
Víctor Antonio Blanco-Palmero 1,2,3,† , Marcos Rubio-Fernández 1,2,†, Desireé Antequera 1,2,
Alberto Villarejo-Galende 1,2,3 , José Antonio Molina 1,2,3, Isidro Ferrer 1,4,5,6 , Fernando Bartolome 1,2,*




Rubio-Fernández, M.; Antequera, D.;
Villarejo-Galende, A.; Molina, J.A.;
Ferrer, I.; Bartolome, F.; Carro, E.
Increased YKL-40 but Not C-Reactive
Protein Levels in Patients with
Alzheimer’s Disease. Biomedicines
2021, 9, 1094. https://doi.org/
10.3390/biomedicines9091094
Academic Editor: Lorenzo Falsetti
Received: 21 July 2021
Accepted: 23 August 2021
Published: 27 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain;
victorb1989@gmail.com (V.A.B.-P.); marcosrubio.imas12@h12o.es (M.R.-F.); eeara@yahoo.es (D.A.);
avgalende@yahoo.es (A.V.-G.); cvillaiza@telefonica.net (J.A.M.); 8082ifa@gmail.com (I.F.)
2 Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12),
28041 Madrid, Spain
3 Neurology Service Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
4 Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, E08907 Barcelona, Spain
5 Department of Pathology and Experimental Therapeutics, University of Barcelona, E08900 Barcelona, Spain
6 Institute of Neurosciences, University of Barcelona, E08000 Barcelona, Spain
* Correspondence: fbartolome.imas12@h12o.es (F.B.); carroeva@h12o.es (E.C.); Tel.: +34-913908765 (F.B. & E.C.);
Fax: +34-913908544 (F.B. & E.C.)
† These authors contributed equally to this work.
Abstract: Neuroinflammation is a common feature in Alzheimer’s (AD) and Parkinson’s (PD) disease.
In the last few decades, a testable hypothesis was proposed that protein-unfolding events might
occur due to neuroinflammatory cascades involving alterations in the crosstalk between glial cells
and neurons. Here, we tried to clarify the pattern of two of the most promising biomarkers of
neuroinflammation in cerebrospinal fluid (CSF) in AD and PD. This study included cognitively
unimpaired elderly patients, patients with mild cognitive impairment, patients with AD dementia,
and patients with PD. CSF samples were analyzed for YKL-40 and C-reactive protein (CRP). We found
that CSF YKL-40 levels were significantly increased only in dementia stages of AD. Additionally,
increased YKL-40 levels were found in the cerebral orbitofrontal cortex from AD patients in agreement
with augmented astrogliosis. Our study confirms that these biomarkers of neuroinflammation are
differently detected in CSF from AD and PD patients.
Keywords: Alzheimer’s disease; Parkinson’s disease; YKL-40; C-reactive protein; CSF and plasma
biomarkers; inflammation; astrogliosis
1. Introduction
Neuroinflammation is now widely accepted as a pathological hallmark of Alzheimer’s
(AD) [1,2] and Parkinson’s (PD) [3–5] disease. Several damage signals appear to induce
neuroinflammation, including β-amyloid (Aβ) oligomers, tau, and α-synuclein (α-syn), me-
diated by the progressive astrocyte and microglial cell activation with the consequent over-
production of proinflammatory agents that may leak toward cerebrospinal fluid (CSF) [6].
Despite the analysis of these agents in CSF being a tempting topic to study, levels of inflam-
matory markers in CSF from AD and PD patients have not been sufficiently investigated.
A standard clinical application of inflammatory markers in the clinical diagnosis of these
neurodegenerative disorders is lacking, likely owing to contradictory and heterogeneous
findings of numerous studies [7,8].
Among these neuroinflammatory markers found in biological samples is YKL-40 (also
named Chitinase 3-like I). This marker has been largely associated with the pathogenesis
of a variety of human diseases, many of them sharing chronic inflammatory features
and high cellular activity, including rheumatoid arthritis, hepatic fibrosis, and asthma,
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where YKL-40 levels were found elevated in patient peripheral blood [9–11]. YKL-40 is a
secreted glycoprotein with functions including tissue remodeling during inflammation and
angiogenic processes, which make YKL-40 a good marker of inflammation and endothelial
dysfunction [12–14]. YKL-40 was found elevated in CSF from several acute and chronic
neuroinflammatory conditions [15], as well as in preclinical and prodromal AD/mild
cognitive impairment (MCI) [16–18]. This is consistent with the potential role of astrocytosis
in early AD pathogenesis [19] and with the fact that YKL-40 expression and YKL-40
protein levels are abundant in reactive astrocytes and residual in microglial cells [15,20,21].
Additionally, YKL-40 was found close to amyloid plaques and neurofibrillary tangles
in AD [16]. Contrarily, other works reported different results showing no significant
differences in YKL-40 levels in CSF from MCI and AD patients compared with cognitively
normal subjects [22]. Other works indicated increased CSF YKL-40 levels only in AD
but not in MCI subjects compared with healthy controls [23,24]. Regarding PD, YKL-40
concentrations in CSF were found either decreased or unchanged [25,26].
Although YKL-40 can be considered one of the most promising neuroinflammatory
biomarkers in AD, the abovementioned works indicate that brain YKL-40 levels patterns
in different neurodegenerative diseases and the potential correlation between brain and
CSF levels is largely unknown, indicating that more research regarding YKL-40 expression
pattern is required.
On the other hand, C-reactive protein (CRP), a kind of acute-phase protein regulated
by proinflammatory cytokines, is the most studied biomarker of systemic inflammation [27].
CRP was linked to chronic inflammatory and neurodegenerative diseases, such as AD
and PD [28]. Elevated CRP peripheral blood levels have been frequently associated with
increased risk of dementia and cognitive decline. Studies carried out investigating the
association between markers of inflammation and risk of dementia showed conflicting
results. A systematic review and meta-analysis found that elevation of peripheral CRP
levels was associated with increased risk of developing dementia [29]. Nevertheless, an-
other meta-analysis found no significant differences in serum CRP levels between patients
with AD and healthy subjects [30]. Epidemiological studies have also explored the re-
lationship between CRP levels and AD risk, describing lower CRP levels in CSF from
AD patients [31,32]. Regarding PD and CRP levels, results in the literature are still con-
tradictory. A significant increase in blood CRP levels was reported in subjects suffering
from PD compared with healthy controls [33,34], while other works did not identify such
a tendency, instead reporting no differences [35]. Furthermore, the CRP levels in CSF
remained unchanged in PD patients when compared with healthy subjects [26,32]. Despite
these differences, CRP is considered a prominent “risk factor” for PD [36].
Growing evidence indicates that blood-borne CRP can cross the blood–brain and
blood–spinal cord barriers; thus, CRP can be found in the CSF and deposited in the
diseased central nervous system (CNS). The source of CRP might also be local. However,
CRP production may occur in multiple CNS-resident cells including neurons, microglia,
and astrocytes [37–39]. Regardless of its origin (hepatic versus local), the presence of
CRP in the CNS is associated with numerous diseases including AD [40]. CRP levels
were also found increased in brain parenchyma tissue after intracerebral hemorrhage [41].
Additionally, large amounts of the protein were present in perihematomal regions and
within neurons and glia of patients who died within 12 h of spontaneous intracerebral
hemorrhage [41,42].
Despite these accumulative data supporting a role of neuroinflammation, particularly
YKL-40 and CRP in AD and PD, there is no definitive evidence reflecting the peripheral
(blood) and central (CSF) concentration changes of YKL-40 and CRP in AD and/or PD
patients. We think that further research is needed to elucidate the variable pattern of these
inflammatory biomarkers in the CSF and blood from AD and PD patients. In this work,
we aimed at clarify YKL-40 and CRP concentrations measured in CSF and plasma and to
determine their specificity in AD and PD. To address this issue, we analyzed YKL-40 and
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CRP levels in CSF and plasma from a well-characterized cohort of patients with MCI, AD,
and PD, using sensitive enzyme-linked immunosorbent assays (ELISAs).
2. Material and Methods
2.1. Human Donors
A total of 123 subjects were included in this study: (1) elderly nondemented subjects
without any evidence of any neurodegenerative disease (healthy controls) classified as
controls (n = 37); (2) MCI due to AD (MCI) patients (n = 22); (3) probable mild/moderate–
severe sporadic AD patients (n = 34); (4) PD patients (n = 30). Study participants were
enrolled from the Memory Clinic (controls, MCI and AD subjects) and Movement Disorders
Unit (PD participants) of Hospital Universitario 12 de Octubre (Madrid, Spain). Subject
demographic and clinical characteristics are listed in Table 1.
Table 1. Demographic and clinical data of participants.
Control PD MCI AD Dementia p Value
n 37 30 22 34 NA
Sex (M/F) 22/15 17/13 7/15 13/21 ns
Age, mean (SD), y 68.18 (11.2) 66.39 (9.9) 69.40 (6.4) 73.53 (8.9) a <0.05
Age at onset, mean
(SD), y NA 61.48 (10.7) 66.53 (6.7) 70.44 (8.9)
b <0.01
Years since onset,
mean (SD), y NA 3.89 (3.3) 2.87 (1.3) 3.09 (1.4) ns
Hoehn & Yahr
(1/2/3/4/5) NA 11/11/6/2/0 NA NA NA
CDR (0.5/1/2/3) NA NA 22/0/0/0 0/25/9/0 NA
APOE ε 4 carrier,
No. (%) 1
c,d - 54 32.4 <0.0001
AD: Alzheimer’s disease; MCI: mild cognitive impairment. PD: Parkinson’s disease; n: number; F: female; ns: non-significant; y: year; M:
male; SD: standard deviation; NA, not applicable; CDR: Clinical Dementia Rating. p value indicates statistical difference within the cohort1;
-: not obtained data; a p < 0.05 vs PD; b p < 0.01 vs. PD; c p < 0.0001 vs. AD; d p < 0.0001 vs. PD.
All participants were classified using established diagnostic criteria into those with
MCI or probable AD dementia [43–45]. Diagnosis was based on detailed clinical assess-
ment, neuropsychological evaluation, and neuroimaging (MRI). Functional impairment
was measured via the Clinical Dementia Rating (CDR) score [46]. PD patients were diag-
nosed following the Movement Disorder Society (MDS) clinical diagnostic criteria [47],
and all fulfilled criteria for clinically established PD. PD patients did not refer cognitive
complaints and did not exhibit symptoms of dementia. The control group was constituted
by cognitively normal individuals aged 50 years or older, without clinical signs of cognitive
impairment and without neurological or psychiatric disease history. Exclusion criteria for
every participant were concomitant significant cerebrovascular disease and evidence of
any neurological, psychiatric, medication, or non-neurological medical comorbidity that
could affect cognition or motor function.
Approval of the study was obtained from the Research Ethics Committee of Hospital
Universitario 12 de Octubre, and all participants provided written informed consent.
2.2. Fluid Sample Collection
CSF samples were collected from all subjects (including healthy patients and MCI,
AD, and PD subjects) and processed according to standardized procedures by lumbar
puncture in 15 mL sterile polypropylene tubes. Samples were then centrifuged at 3000 rpm
at 4 ◦C for 10 min. Supernatant aliquots were stored at −80 ◦C into 0.5 mL polypropylene
cryogenic tubes with Protease Inhibitor Cocktail (Roche, Basel, Switzerland).
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Blood samples were obtained through antecubital vein puncture from patients and
healthy subjects. Plasma was isolated from whole blood collected in 7 mL EDTA-2Na tubes.
Whole blood was centrifuged at 2000 rpm for 10 min at room temperature. Supernatants
were then collected and aliquoted in polypropylene cryogenic tubes with Protease Inhibitor
Cocktail (Roche, Basel, Switzerland) and stored at −80 ◦C.
2.3. Tissue Samples
Postmortem cerebral orbitofrontal cortex tissue was obtained from brain donors
diagnosed with AD and control individuals. Frozen samples were supplied by the Institute
of Neuropathology Brain Bank IDIBELL-Hospital Universitari de Bellvitge (Hospitalet de
Llobregat, Spain). Subject consent was obtained according to the Declaration of Helsinki,
and approval came from the Research Ethics Committee of the responsible institution.
For all cases, written informed consent was available. Subjects were selected on the basis
of postmortem diagnosis of AD according to neurofibrillary tangle pathology and Aβ
plaques [48]. AD cases showed high AD neuropathologic change (Braak stage V/VI and
moderate to frequent neuritic plaque score). Control participants were considered those
with/without neurological symptoms or a low grade of AD neuropathologic change. A
total of 24 samples were categorized into AD and controls, as presented in Table 2.
Table 2. Demographic and clinical data of brain tissue donors.
Control AD
n 12 12
Sex (M/F) 6/6 6/6







AD: Alzheimer’s disease; n: number; F: female. M: male; SD: standard deviation.
2.4. DNA Purification and Apolipoprotein E (APOE) Genotyping
Genomic DNA was extracted from peripheral blood using QIAmp DNA Blood Mini
Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Human
APOE C112R and R158C polymorphisms were detected to identify the APOE ε2, ε3, and ε4
alleles, using the LightCycler 480 II Instruments Kit (Roche Diagnostics, Basel, Switzerland)
following manufacturer instructions.
2.5. Protein Analysis
CSF and plasma concentrations of the neuroinflammatory biomarkers (YKL-40 and
CRP) were analyzed using ELISA kits (Human Chitinase 3-like 1 Quantikine ELISA kit
(DC3L10), R&D; Human CRP Quantikine ELISA kit (DCRP00), R&D) according to the
manufacturer’s instructions.
Brain YKL-40 and GFAP protein levels were also examined by Western blotting. Post-
mortem cerebral orbitofrontal cortex tissue was obtained from brain donors diagnosed
with AD and control individuals. Briefly, human cerebral orbitofrontal cortex samples
were incubated and homogenized in lysis buffer (50 mM Tris/HCl buffer, pH 7.4 contain-
ing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM PMSF, Protease and Phosphatase Inhibitor
Cocktails; Roche, Basel, Switzerland) and centrifuged for 10 min at 14,000 rpm at 4 ◦C.
Supernatants were recovered and stored at −80 ◦C. Protein content was determined using
the BCA method (Thermo Fisher Scientific, MA, USA). Equal amounts of protein (20 µg
for YKL-40 and 5 µg for GFAP) were mixed with Laemmli sample buffer supplemented
with β-mercaptoethanol, heated to 95 ◦C for 5 min, resolved by 10% NuPAGE Bis-Tris
Gels (Thermo Fisher Scientific, MA, USA), and transferred onto polyvinylidene difluo-
ride (PVDF) membranes (Millipore, MA, USA). Afterward, membranes were blocked and
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incubated overnight at 4 ◦C with primary antibodies: a recombinant rabbit monoclonal
anti-YKL-40 antibody (ab255297, 1:500, Abcam) and a mouse monoclonal anti-GFAP an-
tibody (G3893, 1:0000, Sigma Aldrich). Membranes were then incubated for 1 h with
the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (G-21234,
1:5000, Thermo Fisher Scientific, MA, USA; ab97023, 1:40000, Abcam). Protein loading
was monitored using mouse monoclonal HRP-conjugated antibodies against α-tubulin
(ab40742, 1:5000, Abcam) for YKL-40 or against β-actin (A1978, Sigma Aldrich) for GFAP
detection. Immunocomplexes were revealed by an enhanced chemiluminescence reagent
(ECL Clarity; Bio Rad, CA, USA). Densitometric quantification was carried out with Image
Studio Lite 5.0 software (Li-COR Biosciences, NE, USA). Protein bands were normalized to
loading controls and expressed as a percentage of the control group.
2.6. Statistical Analysis
Statistical analysis and graphs were performed using Stata/IC software (Stata 16.1,
StataCorp LLC, College Station, TX, USA) and Prism (GraphPad Software version 8.00,
La Jolla, CA, USA). After assessing the normality of the distribution, differences in CSF
and plasma YKL-40 and CRP levels between groups were analyzed using the nonpara-
metric Kruskal–Wallis rank test. The p-value for pairwise comparisons is displayed with
Bonferroni correction. A descriptive multiple linear regression model was performed to
account for confounding variables (age, sex, and APOE ε4) in CSF YKL-40 association
analysis. Interactions of confounding variables with the clinical diagnosis were excluded
from the model (significance for the whole set of interactions: p > 0.10). The regression
coefficient is displayed as “b”. Differences in sex distribution, age of participants, age at
onset, and years since the onset of the disease between groups were evaluated with Pearson
chi-squared and ANOVA tests, where appropriate. Associations between biomarkers and
demographic characteristics were examined with Pearson correlation tests, Student t-tests
and Mann–Whitney U tests, where appropriate. A nonparametric trend test (Jonckheere
trend test) was performed to evaluate the existence of a trend when the exposition showed
ordinal categories. ROC curves were constructed after modeling the presence or absence of
a given clinical diagnosis with a regression logistic analysis. YKL-40 and GFAP Western
blot expression levels were normalized to their respective loading controls (α-tubulin
and β-actin) and compared with the mean of the control ratio with the nonparametric
Mann–Whitney U test. In graphs, CSF and plasma YKL-40 and CRP levels are shown as
median and interquartile range. The brain expression of YKL-40 is shown as the mean ±
standard error of the mean (SEM). In all cases, statistical significance was set at p < 0.05.
3. Results
3.1. Associations with Demographic Data
Demographic and clinical data are shown in Table 1 for further characterization of the
study cohort. A total of 34 subjects were clinically diagnosed with AD, 22 subjects were
grouped as MCI, and 30 subjects were diagnosed with PD. Individuals diagnosed with AD
were slightly older than the rest of the cohort, including PD, MCI, and healthy subjects.
Female sex was overrepresented in the AD and MCI groups, while males represented
around 60% of controls and PD subjects. APOE ε4 carriers were more prevalent in the
MCI/AD group than in controls, according to previous publications [49]. Most AD patients
had clinically mild dementia (74% scored 1 in CDR scale), and none of the PD patients
reached the dementia stage. Furthermore, the majority of individuals diagnosed with PD
exhibited mild motor impairment (73% of them were in Hoehn & Yahr stage 1 or 2).
3.2. YKL-40 and CRP Levels in Different Diagnostic Groups
YKL-40 and CRP levels across all clinical groups are illustrated in Figure 1. In CSF,
YKL-40 levels were different among groups and were found to increase in AD dementia
subjects compared with healthy controls (Figure 1A). No differences were found in YKL-
40 levels between healthy controls and MCI or PD groups in CSF (Figure 1A). Nevertheless,
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a trend toward reduced levels was observed in PD patients, which were significantly lower
compared to AD and MCI patient groups (Figure 1A). In plasma, YKL-40 levels remained
unchanged across all clinical groups (Figure 1B).
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Figure 1. YKL-40 and CRP levels in CSF and plasma in different diagnostic groups. Box-and-whisker plots showing
(A,B) YKL-40 and CRP levels (C,D) in CSF and plasma, respectively, across the diagnostic groups. Differences between
groups were assessed using Kruskal–Wallis test followed by Bonferroni correction. * p < 0.05; *** p < 0.001; **** p < 0.0001.
MCI, mild cognitive i pairment; AD, Alzheimer’s disease dementia; PD, Parkinson’s disease. ns: non-significant.
A nonparametric trend test did not show any statistically significant rising tendency
of CSF (p = 0.48) or plasma (p = 0.053) YKL-40 levels along with MCI or mild and moderate
AD. When adjusting for age, sex, and APOE ε4 status, levels of CSF YKL-40 remained high
in AD dementia patients when compared with controls (b = 125.5 ng/mL, 95% CI = 19.1 to
232.0 ng/mL, p < 0.05).
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Regarding CRP levels in CSF and plasma, we did not find significant differences
between healthy subjects and AD, MCI, and PD patients (Figure 1C,D). Our results are con-
sistent with previous studies indicating no differences in CRP levels from CSF comparing
healthy subjects and PD patients [26] or in serum CRP levels between patients with AD
and healthy subjects [30].
In order to analyze the discriminative ability of both biomarkers for the diagnosis of PD
and AD, we performed a logistic regression analysis and calculated the corresponding ROC
curve for each CSF biomarker and diagnosis. CSF YKL-40 differentiated AD patients from
the rest of the cohort, including PD, MCI, and healthy subjects, with 65.6% sensitivity and
66.3% specificity (AUC = 0.69, 95%CI = 0.58 to 0.80, cutoff point = 316.5 ng/mL) (Figure 2A).
The combination with CSF CRP did not improve the performance. Nevertheless, for the
diagnosis of PD, the combination of CSF YKL-40 and CRP yielded the best results, showing
a moderate discriminative ability (AUC = 0.82, 95% CI =0.73 to 0.89, cutoff point of the
model = 0.300), with 79.2% sensitivity and 82.1% specificity (Figure 2B).
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Figure 2. Receiver operating characteristic (ROC) analysis of YKL-40 and CRP levels in CSF. (A) ROC curve and its
corresponding area under the curve (AUC) differentiating YKL-40 levels in CSF from AD patients and non-AD subjects
including control subjects. (B) AUC differentiating the combination of YKL-40 and CRP levels in CSF from PD and non-PD
patients. AUC, area under the curve; AD, Alzheimer’s disease dementia; PD, Parkinson’s disease.
3.3. Correlations between YKL-40 and CRP Levels in Plasma and CSF
B th CSF YKL-40 (r = 0.39, p < 0.001; Figure 3A) CRP (r = 0.56, p < 0.0001;
Figure 3B) correlated significantly with their respective plasma concentrations in the whole
cohort. The stronger positive correlation was found in AD patients (YKL-40: r = 0.69, CRP:
r = 0.84).
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Figure 3. Correlation between YKL-40 and CRP levels in CSF and plasma, and between YKL-40 and age in the study cohort.
Correlations between the expression levels of (A) YKL-40 and (B) CRP in CSF and plasma in the study cohort. Correlation
between (C) CSF and (D) plasma YKL-40 and age within the diagnostic group. Correlations were examined with Pearson
correlation test. MCI, mild cognitive impairment; AD, Alzheimer’s disease dementia; PD, Parkinson’s disease.
In the whole cohort, plasma and CSF YKL-40 levels positively correlated with age (CSF
YKL-40: r = 0.38, p < 0.0001; Figure 3C; plasma YKL-40: r = 0.57, p < 0.0001; Figure 3D). This
correlation was especially stronger for the control group (CSF YKL-40: r = 0.46, p < 0.01;
plasma YKL-40: r = 0.84, p < 0.0001). No statistically significant correlation with age was
found in the plas a and CSF CRP analysis. Furthermore, the time since symptom onset
did not correl te with any biomarker level in any group. Plasma and CSF YKL-40 and CRP
levels did not differ by sex or by the presence of an APOE ε4 allele.
3.4. YKL-40 Levels in AD Brain
Upon inflammation, YKL-40 s p duced and ecreted by many cells including vascu-
lar smooth muscle c lls and m crophages [50]. In the brain, YKL-40 is mainly express d
in reactive astrocytes [20,25]. Thus, we investigated if the observed incr ase in YKL-40
l l in CSF from AD patients could be associated wit higher YKL-40 levels in c bral
parenchyma. To ex lore this hypo hesis, we examined the YKL-40 c llular levels in hum n
brain tissue from AD patients a d healthy subjects. Immunoblotting showed that YKL-40
levels in cer bral orbitofrontal cortex samples were significantly increased in AD patients
compared with healthy subjects (Figure 4A). To determine if increased levels of YKL-40 in
cerebral orbitofrontal cortex were associated with astrocyte reactivity, the levels of GFAP
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were also analyzed. Western blotting showed that GFAP levels were also higher in AD
samples compared to those observed in control subjects (Figure 4B) in parallel with the
observed rise in YKL-40 levels, proving that AD astrogliosis increases YKL-40 levels.Biomedicines 2021, 9, x FOR PEER REVIEW 9 of 14 
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Figure 4. YKL-40 and GFAP levels in cerebral orbitofrontal cortex of AD patients and control group. Western blot analysis
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4. Discussion
In this cross-sectional study, we showed a variable pattern of the inflammatory
biomarkers YKL-40 and CRP in AD and PD patients. We confirmed that YKL-40 lev-
els are significantly increased in CSF from AD patients compared to healthy controls,
indicating an inflammatory response at the dementia stage. Such an increase was not seen
in MCI or PD patients, where CSF YKL-40 levels remained unchanged. These results were
also extended to the cerebral orbitofrontal cortex where we found that YKL-40 expression
was augmented in AD patients, suggesting glial activation, thus corroborating our hypoth-
esis. Another finding in this study was related to CRP levels in CSF and plasma. We found
lower CRP levels in CSF from PD patients compared with other groups (AD, MCI, and
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healthy subjects), but this change did not reach statistical significance. Furthermore, we
did not find evidence of significant alterations in plasma for YKL-40 or CRP.
Inflammation is increasingly recognized as part of the pathology of neurodegenerative
conditions, including AD and PD. Evidence proposes that neurodegeneration occurs in part
because the CNS environment is affected by a cascade of events collectively named neuroin-
flammation [51]. Despite biomarkers of neuroinflammation being useful for monitoring
disease diagnosis, progression, and response to therapy, accurate and reliable biomarkers
for many neurological diseases are scarce. In recent years, the interest in new neuroinflam-
matory biomarkers has grown at early and symptomatic stages of these diseases. Blood
and CSF are commonly used to monitor biomarkers of neuroinflammation, with many
of them being the consequence of the CNS pathology. Some examples are the levels of
cytokines and chemokines, the loss of blood–brain barrier integrity, and neuronal damage
indicators [52].
Only a few studies have shown the possibility of analyzing YKL-40 levels in CSF and
blood from patients with AD and predementia stages. One of these studies found that
YKL-40 concentration in CSF from AD patients was significantly elevated compared to
cognitively normal subjects, with an AUC = 0.88 pointing to the potential value of YKL-40
levels in CSF for AD diagnosis [53]. Increased YKL-40 levels were observed not only
in AD dementia, but also in the prodromal phase of AD when compared to cognitively
normal controls [54]. Similar observations were found in patients with AD, where YKL-40
concentration in CSF was increased in very mild and mild dementia subjects in comparison
with cognitively normal individuals [16]. In our study, we found a trend of increased
YKL-40 levels in CSF from MCI subjects compared with healthy controls, and this increase
was evident in AD patients. However, the resulting AUC in our study was lower; thus, we
propose that YKL-40 might only be a modest AD biomarker candidate.
Significantly increased chitinase-3 like 3 (CHI3L3) mRNA expression, a mouse homolog
of YKL-40, was found in brains of AD mice models when compared to age-matched con-
trols [55]. Similarly, in autopsied human brain samples from pathologically confirmed
AD subjects, YKL-40 mRNA levels were significantly increased in comparison with non-
demented controls [55]. Although there is no clear explanation regarding which factors
modulate YKL-40 levels in AD, it has been suggested that elevated YKL-40 expression and
protein levels might result from increased astrocytic reactivity and release in brain [21]. It
was shown that astrocytes in the close vicinity of amyloid plaques were immunoreactive
for YKL-40, which confirms the involvement of this protein in the neuroinflammatory
response to Aβ deposition [16]. It is known that insoluble Aβ aggregates may induce
inflammatory reactions and activation of microglia, resulting in increased proinflammatory
mediator production. The relationship between YKL-40 and amyloid-related pathways
in AD development was further discussed [17,25]. It seems that the YKL-40 concentra-
tion in CSF may be linked to AD pathology, particularly astrogliosis. Indeed, it has been
shown that YKL-40 is expressed by reactive astrocytes GFAP+ in AD [25]. Thus, increased
expression of YKL-40 and protein levels in reactive astrocytes may be reflected in the CSF,
indicating that astrocyte-associated metabolites may be utilized as potential biomarkers.
Although data regarding elevated YKL-40 levels in CSF from early stages of AD are contra-
dictory [16,17,22–24,54], our results support the increase in YKL-40 levels in CSF from AD
subjects, as well as the increased astrocytic YKL-40 levels associated with astrocytosis.
Interestingly, we found that YKL-40 levels in CSF from PD patients were significantly
lower compared with those levels in AD subjects suggesting that YKL-40, a marker of
astroglial activation, is downregulated in PD. It was reported that YKL-40 levels were
decreased in synucleinopathies when compared with tauopathies, suggesting that glial acti-
vation may be lower in brains from PD patients and other synucleinopathies in comparison
with patients who have tauopathies or healthy controls [26,56]. These data may suggest
that CSF YKL-40, as a marker of astroglial activation, is downregulated in PD. Despite
astrocytes exerting protection against the inflammatory response in PD [57,58], astroglial
dysfunction due to α-syn inclusions may occur simultaneously. In vitro evidence showed
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that astrocytes are able to efficiently degrade the α-syn aggregates from the extracellular
space [59]. More recently, it was shown that primary rat astrocytes receive α-syn aggre-
gates from neurons in mixed cell culture and efficiently transfer them from astrocyte to
astrocyte [60]. It is possible that the increase in α-syn levels in astrocytes is a consequence
of an endocytic mechanism upon high α-syn levels from the extracellular space, leading to
the typical α-syn astrocytic inclusions in PD brains [61]. This accumulation could then lead
to the dysregulation of other astrocytic functions, including YKL-40 production/secretion.
Our study yielded no significant changes for CRP levels in CSF or in plasma from AD
and PD subjects, although others have described contradictory results [30–32,34]. Patholog-
ical studies have demonstrated that CRP is present in the senile plaques and neurofibrillary
tangles in AD brains, suggesting that this protein may play a role in the neuropathologi-
cal processes in AD [62–64]. In PD, aggregated α-syn can promote microglial activation
and stimulate the secretion of inflammatory molecules, including CRP [65], thus evoking
neuroinflammation [66].
CRP is primarily produced in the liver but is also generated in neurons to a lesser
extent [41]. Such residual production of CRP in the CNS does not appear to contribute
significantly to CSF levels [39].
In summary, our present study revealed a different inflammatory biomarker profile
in individuals with AD and PD. CSF YKL-40 levels were significantly elevated in the AD
group, and this increment corroborated the analysis of the YKL-40 protein levels in the
cerebral orbitofrontal cortex from pathologically confirmed AD subjects. In PD individuals,
plasma and CSF CRP and YKL-40 levels remained unchanged. Notwithstanding, we
identified a moderate discriminative ability by combining both biomarkers in CSF for PD
diagnosis. Together, our data support the involvement of both inflammatory proteins in
the pathogenesis of neurodegenerative diseases.
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